Published in J Hematol Oncol on November 26, 2010
Abl family kinases modulate T cell-mediated inflammation and chemokine-induced migration through the adaptor HEF1 and the GTPase Rap1. Sci Signal (2012) 1.57
Current management and novel agents for malignant melanoma. J Hematol Oncol (2012) 1.53
Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol (2011) 1.04
Targeting the RAS pathway in melanoma. Trends Mol Med (2011) 0.98
Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia. J Hematol Oncol (2012) 0.94
Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis. Mol Pharm (2011) 0.89
IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. Mol Cancer Ther (2013) 0.89
The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation. J Hematol Oncol (2014) 0.88
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells. PLoS One (2013) 0.88
New insights into antigen specific immunotherapy for chronic myeloid leukemia. Cancer Cell Int (2012) 0.88
The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells. PLoS One (2011) 0.87
Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line. J Hematol Oncol (2011) 0.86
Phosphorylation events during viral infections provide potential therapeutic targets. Rev Med Virol (2011) 0.86
Development of a highly sensitive method for detection of JAK2V617F. J Hematol Oncol (2011) 0.85
Gene expression profiles in BCL11B-siRNA treated malignant T cells. J Hematol Oncol (2011) 0.85
CD44 targets Wnt/β-catenin pathway to mediate the proliferation of K562 cells. Cancer Cell Int (2013) 0.83
A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients. J Hematol Oncol (2011) 0.83
Increased killing of SCCVII squamous cell carcinoma cells after the combination of Pc 4 photodynamic therapy and dasatinib is associated with enhanced caspase-3 activity and ceramide synthase 1 upregulation. Int J Oncol (2013) 0.80
Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies. Int J Rheumatol (2011) 0.79
Imatinib mesylate therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: an experience from eastern India. Indian J Hematol Blood Transfus (2011) 0.79
Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev Anticancer Ther (2013) 0.78
Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells. Oncotarget (2015) 0.76
Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors. PLoS One (2013) 0.76
Successful nilotinib treatment in a child with chronic myeloid leukemia. Case Rep Oncol (2015) 0.75
Antimalarial activity of kinase inhibitor, nilotinib, in vitro and in vivo. J Antibiot (Tokyo) (2015) 0.75
MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells. PLoS One (2016) 0.75
Imatinib for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2015) 0.75
4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines. Invest New Drugs (2016) 0.75
Adherence to medication. N Engl J Med (2005) 39.77
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med (2010) 10.64
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2010) 9.77
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med (2006) 9.07
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med (2006) 8.26
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell (2009) 6.97
The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med (1995) 6.73
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res (2005) 5.98
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol (2010) 4.21
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol (2008) 3.85
Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet (1996) 3.77
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood (2009) 3.47
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res (2006) 3.28
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol (2009) 3.07
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol (2009) 2.78
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res (2006) 2.72
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood (2006) 2.50
Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem (2008) 2.09
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood (2009) 2.00
Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics (2007) 1.87
The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood (2009) 1.84
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia (2006) 1.83
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica (2007) 1.76
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol (2008) 1.76
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood (2008) 1.51
Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood (2007) 1.40
Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia (2009) 1.33
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol (2009) 1.29
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica (2007) 1.18
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer (2009) 1.15
Tyrosine kinase inhibitors: the first decade. Curr Hematol Malig Rep (2010) 1.11
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia (2007) 1.07
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med (2007) 0.92
Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther (2009) 0.91
Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. Recent Results Cancer Res (2010) 0.91
Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. Anticancer Agents Med Chem (2010) 0.87
New dosing schedules of dasatinib for CML and adverse event management. J Hematol Oncol (2009) 0.84
First-line therapy for chronic myeloid leukemia: new horizons and an update. Clin Lymphoma Myeloma Leuk (2010) 0.84
New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia. Clin Cancer Res (2010) 0.82
Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience. Leuk Res (2007) 0.78
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood (2010) 5.95
Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med (2015) 3.42
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol (2010) 2.94
Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica (2006) 2.75
Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity (2012) 2.16
Nuclear miRNA regulates the mitochondrial genome in the heart. Circ Res (2012) 1.95
Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol (2013) 1.92
MEK and the inhibitors: from bench to bedside. J Hematol Oncol (2013) 1.90
Fetal mouse phthalate exposure shows that Gonocyte multinucleation is not associated with decreased testicular testosterone. Toxicol Sci (2007) 1.75
Current management and novel agents for malignant melanoma. J Hematol Oncol (2012) 1.53
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res (2013) 1.43
Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol (2012) 1.30
Reversal in multidrug resistance by magnetic nanoparticle of Fe3O4 loaded with adriamycin and tetrandrine in K562/A02 leukemic cells. Int J Nanomedicine (2008) 1.29
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol (2009) 1.24
Current management and prognostic features for gastrointestinal stromal tumor (GIST). Exp Hematol Oncol (2012) 1.23
p38 mitogen-activated protein kinase plays an inhibitory role in hepatic lipogenesis. J Biol Chem (2006) 1.23
Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J Hematol Oncol (2010) 1.18
STAT inhibitors for cancer therapy. J Hematol Oncol (2013) 1.16
Recent advances and novel agents for gastrointestinal stromal tumor (GIST). J Hematol Oncol (2012) 1.16
Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res (2011) 1.14
Human parvovirus B19 causes cell cycle arrest of human erythroid progenitors via deregulation of the E2F family of transcription factors. J Clin Invest (2010) 1.14
B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol (2013) 1.14
Ingestion of an isothiocyanate metabolite from cruciferous vegetables inhibits growth of human prostate cancer cell xenografts by apoptosis and cell cycle arrest. Carcinogenesis (2004) 1.13
Targeting cell cycle machinery as a molecular mechanism of sulforaphane in prostate cancer prevention. Int J Oncol (2004) 1.12
Dietary nitrate and nitrite modulate blood and organ nitrite and the cellular ischemic stress response. Free Radic Biol Med (2009) 1.12
Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol (2006) 1.11
Microarray-based characterization of a colony assay used to investigate endothelial progenitor cells and relevance to endothelial function in humans. Arterioscler Thromb Vasc Biol (2009) 0.99
A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol (2011) 0.99
Testicular gene expression profiling following prepubertal rat mono-(2-ethylhexyl) phthalate exposure suggests a common initial genetic response at fetal and prepubertal ages. Toxicol Sci (2006) 0.99
P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol (2008) 0.95
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol (2012) 0.94
Sox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia. Blood (2011) 0.92
Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim. J Clin Oncol (2005) 0.92
Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther (2009) 0.91
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol (2012) 0.91
CD146+ T lymphocytes are increased in both the peripheral circulation and in the synovial effusions of patients with various musculoskeletal diseases and display pro-inflammatory gene profiles. Cytometry B Clin Cytom (2010) 0.89
Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol (2008) 0.89
Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol (2002) 0.86
Severe toxicity following induction chemotherapy for acute myelogenous leukemia in a patient with Werner's syndrome. Leuk Lymphoma (2005) 0.84
Palladium-catalyzed allylic alkylation of simple ketones with allylic alcohols and its mechanistic study. Angew Chem Int Ed Engl (2014) 0.84
The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivo. Oncol Rep (2006) 0.84
miR-222 contributes to sex-dimorphic cardiac eNOS expression via ets-1. Physiol Genomics (2013) 0.84
High fat diet reduces the expression of glutathione peroxidase 3 in mouse prostate. Prostate (2011) 0.82
PET scan-positive cat scratch disease in a patient with T cell lymphoblastic lymphoma. Leuk Res (2005) 0.80
Efficient palladium-catalyzed asymmetric allylic alkylation of ketones and aldehydes. Org Biomol Chem (2011) 0.80
C-N bond cleavage of allylic amines via hydrogen bond activation with alcohol solvents in Pd-catalyzed allylic alkylation of carbonyl compounds. J Am Chem Soc (2011) 0.79
Acute promyelocytic leukemia with tetraploid karyotype: first report in the Western hemisphere and update of previous reports. Leuk Res (2011) 0.79
T-cryptantigen (TCA) activation in sever pneumonia complicated with multiple organ failure. Transfus Apher Sci (2010) 0.79
Deficient histone acetylation in acute leukemia and the correction by an isothiocyanate. Acta Haematol (2009) 0.79
[Coblation-assisting uvulopalatopharyngoplasty combining coblation-channeling of the tongue for patients with severe OSAHS]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2012) 0.78
Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials. Biomark Res (2013) 0.78
Coexistence of inversion 16 and the Philadelphia chromosome in patients with acute myelogenous leukemia. Leuk Lymphoma (2002) 0.77
Novel influenza A (H1N1) in patients with hematologic malignancies. J Clin Oncol (2009) 0.77
[Modulation of histone acetylation and induction of apoptosis in SMMC-7721 cells by phenylhexyl isothiocyanate]. Zhonghua Zhong Liu Za Zhi (2010) 0.76
Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leuk Res (2009) 0.76
Prospective evaluation of 2009 H1N1 influenza A in patients admitted with fever to an oncology unit. Infect Control Hosp Epidemiol (2011) 0.76
t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis. Cancer Invest (2009) 0.76
Hydrogen-bond-activated palladium-catalyzed allylic alkylation via allylic alkyl ethers: challenging leaving groups. Org Lett (2014) 0.76
Journal of hematology & oncology: a journal open to all. J Hematol Oncol (2008) 0.75
Phenotypic and functional characterization of a mouse model of targeted Pig-a deletion in hematopoietic cells. Haematologica (2009) 0.75
Sweet fruit from a poisonous kiss. J Hematol Oncol (2010) 0.75
The synthesis of chiral β-aryl-α,β-unsaturated amino alcohols via a Pd-catalyzed asymmetric allylic amination. Org Biomol Chem (2013) 0.75
Publish, not perish: Introducing Experimental Hematology & Oncology. Exp Hematol Oncol (2012) 0.75
Severe imatinib-associated muscle edema in patients with chronic myelogenous leukemia and marked leukocytosis. Leuk Lymphoma (2008) 0.75
Highly efficient asymmetric Michael addition of aldehyde to nitroolefin using perhydroindolic acid as a chiral organocatalyst. Org Biomol Chem (2012) 0.75
P-stereogenic PNP pincer-Pd catalyzed intramolecular hydroamination of amino-1,3-dienes. Org Biomol Chem (2015) 0.75
Asymmetric hydrogenation of β-amino ketones with the bimetallic complex RuPHOX-Ru as the chiral catalyst. Org Biomol Chem (2013) 0.75
[Preliminary clinical investigation of coblation-assisted functional endoscopic sinus surgery for chronic sinusitis and nasal polyps]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2011) 0.75
Palladium-catalyzed asymmetric hydrogenation of α-acyloxy-1-arylethanones. Angew Chem Int Ed Engl (2013) 0.75
[Low-temperature plasma assisted via mouth for surgery treating styloid process syndrome]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2012) 0.75
[Clinical observation of coblation under endoscopy on epiglottis cyst]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2014) 0.75
[Advances in treatment of congenital posterior choanal atresia]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2016) 0.75
[Coblation for benign hyperplasia of tongue base under endoscope]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2009) 0.75
Iridium-catalyzed allyl-allyl cross-coupling of allylic carbonates with (E)-1,3-diarylpropenes. Chem Commun (Camb) (2015) 0.75
[EFFECTIVENESS OF POSTERIOR UNILATERAL TRANSPEDICULAR DEBRIDEMENT, BONE GRAFT FUSION, AND PEDICLE SCREW FIXATION FOR THORACOLUMBAL TUBERCULOSIS]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2015) 0.75
[Expression of BDNF and trk B in the cochleas of the aged rats]. Lin Chuang Er Bi Yan Hou Ke Za Zhi (2006) 0.75
Pd-catalyzed asymmetric allylic amination using easily accessible metallocenyl P,N-ligands. Org Biomol Chem (2015) 0.75
[Revaluvation of UPPP and the pharynx in patients with snoring anatomy]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2015) 0.75
[Investigation of reoperation after failure of UPPP]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2009) 0.75
Asymmetric tandem reactions of N-sulfonylimines and α,β-unsaturated aldehydes: an alternative reaction pathway to that of using saturated aldehydes. Chem Commun (Camb) (2014) 0.75
Asymmetric domino reaction of cyclic N-sulfonylimines and simple aldehydes with trans-perhydroindolic acid as an organocatalyst. Org Lett (2014) 0.75
[Coblation-channelling for the tongue]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2014) 0.75
Evaluation of temozolomide in patients with myelodysplastic syndrome. Leuk Lymphoma (2004) 0.75
[Lingual thyroglossal duct cyst treatment by low temperature coblation on endoscope]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2014) 0.75
Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock. Front Med (2014) 0.75
Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution. Leuk Lymphoma (2006) 0.75
Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine. Leuk Lymphoma (2007) 0.75